Empowering Healthcare Through Knowledge
Dr. Olga Oikonomidou
BSc (Hons), MSc, MRes, MD, PhD, FRCP
Senior Clinical Lecturer in Breast Cancer Medicine
Breast Cancer Translational Research Lead
Honorary Consultant Medical Oncologist
Western General Hospital
University of Edinburgh
Dr. Olga Oikonomidou
Dr Olga Oikonomidou is an Academic Consultant Medical Oncologist specializing in breast cancer and the Breast Cancer Translational Research Group Lead at the Institute of Genetics and Cancer at the University of Edinburgh. Other than a degree in Medicine, she holds a BSc in Human Genetics, MSc in Oncology, MRes in Immunology and a PhD in translational medicine. After completing her training in medical oncology at King’s College Hospital and Guy’s Hospital in London, she moved to Edinburgh where she worked as a Senior Clinical Research Fellow in Breast Cancer for 2 years before getting a substantive post as an Academic Consultant Medical Oncologist and setting up her own research group in breast cancer translational research. Her responsibilities are split between running a busy breast oncology practice at the Edinburgh Cancer Centre and leading on breast cancer clinical trials and translational studies. Dr Oikonomidou is a clinical expert for NICE and SMC and participated in multiple technology appraisals since 2015. She has received a number of prestigious grants for her clinical research projects. She is on the TMG of numerous national and international trials. She is currently the global Chief Investigator of 3 international multicentre trials, UK Chief Investigator of 4 clinical trials and the PI for more than 60 trials. Her academic research interest is focused on prediction of biomarkers of response to treatment and clinical trials in breast cancer in all phases.
Dr. Olga Oikonomidou
PERSONAL DETAILS:
Surname: Oikonomidou
Name: Olga
Email : olga.oikonomidou@ed.ac.uk
GMC number : 6159886 (full registration 12/2006)
Place of work : Institute of Genetics & Cancer, Western General Hospital, NHS Lothian, University of Edinburgh, Edinburgh, UK
http://www.ed.ac.uk/profile/olga-oikonomidou
http://www.ed.ac.uk/cancer-centre/research/oikonomidou-group
https://www.ed.ac.uk/cancer-centre/research/oikonomidou-group/translational-research-breast-cancer
EDUCATION
- Degree in Medicine, Medical School (6 years), University of Athens, Greece. Grade: “Distinction”
- PhD in Translational Medicine, Department of Biochemistry and Pathophysiology, Medical School, University of Athens, Greece. Grade: “Distinction”
- MSc/MRes in Clinical and Laboratory Medicine with specialisation in Immunology. Medical School, University of Athens, Greece. Grade: “Distinction”
- MSc in in Oncology and Cellular Pathology. University of Leeds, UK “Distinction”
- BSc (Hons) in Genetics, University of Leeds, UK ‘’First class’’.
QUALIFICATIONS:
- Real World Evidence in Oncology Course: Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. January 2025 – June 2025
- FRCP: Fellowship of the Royal College of Physicians of London (FRCP) September 2020 - current
- Certificate of Advanced Leadership Skills for Women in Academia– Aurora programme September 2020 - June 2021 (online course with mandatory modules, presentations, and assessment)
- Annual Expert Witness Conference Royal College of Surgeons Edinburgh May 2019
- Educational Supervisor Workshop and Accreditation, Royal College of Physicians London October 2016
- Doctors as Leaders Accreditation, Royal College of Physicians London September 2016
- Consultant’s survival guide– How to succeed as a new Consultant. Royal College of Physicians of London June 2015
- Certificate of Completion of Specialist Training (CCST) in Medical OncologySeptember 2014. GMC Specialist Registry September 2014 (King’s College Hospital & Guy’s & St Thomas’ Hospital)
- Advanced Communication Skills Course for Doctors. King’s College Hospital, London, UK November 2011
- Licence to Practice Medicine, Hellenic Republic, Prefectural Authority of Athens – Piraeus, Division of Western Athens, Directorate of Health, Greece (2006)
PRPOFESSIONAL MEMBERSHIPS:
- Royal College of Physicians
- British Medical Association
- Association of Cancer Physicians (UK)
- European Society of Medical Oncology
- American Society of Clinical Oncology
- EORTC Breast Cancer Group
- Scottish Breast Trials Group
COMMITTEE MEMBERSHIPS:
- Scottish Molecular Tumour Board (2024 – present)
- Edinburgh Clinical Trials Unit Management Group (2015 – present)
- Scottish Clinical Trials Group member (2017- present)
- Margaret Lee Fund Steward (2018- present)
- Editorial Board – Frontiers in Oncology
Health Appraisals:
- National Institute for Clinical Excellence Technology Appraisal Committee Member (2017-current)
- Scottish Medicines Consortium Technology Appraisal Committee Member (2016-current)
EXPERT REVIEWER:
Grant Awarding Bodies
- Breast Cancer Grant Reviewer
- CRUK Grant Reviewer
- NIHR expert reviewer
- MRC expert reviewer
- Irish Cancer Society Grant Reviewer
- Yorkshire Cancer Research Fund Reviewer
Peer Reviewer
- European Journal of Cancer, JAMA, BMJ open, Frontiers in Oncology, Cancer, The Breast, Clinical Oncology, Journal of Clinical Therapeutics, NIHR Programme Grants for Applied Research, CRUK, CSO, MRC.
TEACHING & EDUCATION PROVISION:
UNDERGRADUATE EDUCATION
- BSc graduate student projects supervisor in Reproductive cancer; Tutor on the following BSc courses: Reproductive cancer; Cancer biology course; Research skills in reproductive biology course.
- Developed the breast cancer module for these courses (Breast cancer biology, systemic therapies in breast cancer) – attended by students from medicine, biochemistry, pharmacology.
- University of Dundee Medical School year 4 & 5 teaching on breast cancer biology and treatment pathway & mock MDT
- 5/6yr Medical School students in my clinic twice a month
- 2 undergraduate research projects for reproductive biology course
POSTGRADUATE TAUGHT/TRAINING
- ECRC Representative on Edinburgh Clinical Academic Training Fellowship Panel Shortlisting, selecting, and mentoring the academic speciality trainees for entry onto this program.
- TRACC CRFT PhD program mentorship for 2 medical oncology SpRs that led to a successful PhD program.
- Scottish Oncology Course - Scientific Principles Pharmacology Module- 2 lectures per year ‘’CDK4/6 inhibitors in breast cancer’’.
- Pan Scotland Medical Oncology SpR training – 2 lectures/year – topic varies but the last 2 years I gave talks on Neoadjuvant Chemotherapy in HER2+ve cancer and CDK4/6 inhibitors.
- Edinburgh Oncology Course: Systemic treatment and clinical trials data in advanced breast cancer. The course takes place every 2 years at the Royal College of Physicians in Edinburgh.
- Medical and clinical oncology Specialty Registrars teaching – 3-5 lectures/year (various topics including conferences highlights, chemotherapy and immunotherapy in Breast Cancer, the role of NACT in Breast Cancer, targeted agents in Breast Cancer, newly approved drugs in Breast Cancer, TNBC tumour heterogeneity, Breast Cancer subtypes, breast cancer biology.
- Foundation Year 2 doctors teaching University of Edinburgh – 1 lecture/year - University of Edinburgh (Lecture on Academic Medicine and how to pursue)
- POD cast November 2023, University of Edinburgh: a talk on the molecular alterations in cancer genes and the associated signalling pathways used to inform new treatments for precision medicine in cancer.
POSTGRADUATE RESEARCH
- Supervised three PhD and MD students (primary and co-supervisor roles)
- Supervisor -post-doctoral fellow (2000-current)
- 2 new PhD students to start September 2025
POSTGRADUATE EXAMINER
- External examiner for four postgraduate degrees (3 Phds, 1 MD)
- Internal examiner for ( 3 MDs, 2 PhDs)
AUTHOR/EDITOR:
- National Breast Imaging Academy e-Learning for Healthcare programme: national online educational platform available to all breast care professionals launched summer 2021 – I am the Editor of 8 modules in Breast Cancer (out of the 16 modules in the platform with each module including multiple sessions) – developed and revised all learning material in all 8 modules with annual update of all modules.
- Editor - Frontiers in Oncology
- Book chapter: Olga Oikonomidou. “Practical Problems: Hypercalcaemia in breast disease” Surgery: Core Principles & International Practice. 2nd Edition 2017. JP Brothers Medical Publishers.
PHARMA SPONSORED RESEARCH:
Chief Investigator
EMBER 4:A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET.
SERDs are a new development currently under investigation on the MBC setting of patients with HR+ HER2-ve BC. Imlunestrant is a new SERD that is investigated on the early setting on this study. We do know that patients with high-risk breast cancer have high chance of developing resistance to Aromatase Inhibitors and we believe that by changing the AI to this new drug we will reduce the chances of endocrine resistance. The rationale behind the design of this study is supported by the fact that during the recruitment we had a 30% of screening failure because of patients diagnosed with metastatic disease during the screening phase suggesting how important is to identify ways/treatments to tackle the endocrine resistance risk.
EUCHARIS trial – International multicentre retrospective observational study (Pfizer). European Treatment Patterns and Outcomes Associated with First Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study, 856 patients over 4 countries.
Our RWD suggested that first-line palbociclib+AI therapy was associated with a median PFS range of 28.1-48.1 months and a median OS range of 51.3-NE months for patients across 3 European countries. This real-world study adds to a growing body of RWE supporting the clinical effectiveness of palbociclib and other CDK4/6i combination therapies for people with HR+/HER– ABC. Paper has been accepted for publication September 2024 at the ‘’Cancer Research & Treatment’’.
NCRAS National multi-centre study NCRAS ‘’Patient characteristics, treatment patterns, resource utilisation, and outcomes of patients with ER positive/HER2 negative metastatic breast cancer in England – A Cohort Study using the National Cancer Registration and Analysis Service datasets’’ (Sanofi).We collected data on the real-world sequencing treatment patterns in metastatic breast cancer patients in England which will allow the right placement of new agents.
Principal Investigator
- More than 70 clinical trials in breast cancer since 2015 ranging from phase 1b to phase 3 trials.
Trial Management Group Member:
- EUCHARIS trial: International multicentre retrospective observational study (Pfizer). European Treatment Patterns and Outcomes Associated with First Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study, 856 patients over 4 countries.
- FAIM: Randomised open-label phase II study of induction standard of care Fulvestrant and CDK4/6 inhibition with addition of Ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression.
- Plasma MATCH trial: A multiple parallel cohort, open-label, multicentre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening.
- TRAK-ER:Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER).
- 3-Pillars:A phase II open label study of the cyclin-dependent kinase 4/6 inhibitor Palbociclib in combination with letrozole, trastuzumab plus tucatinib as neoadjuvant treatment for ER-positive, PgR-positive and HER2-positive early breast cancer in post-menopausal women.
- Cardiac Care: A multicentre prospective randomised open-label blinded end-point controlled trial of cardiac troponin guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients.
- HER2-CNS SURVEILLANCE: A Study of the feasibility of randomising women and men with HER2 Positive metastatic breast cancer to Central Nervous System surveillance versus not.
AWARDS/DISTINCTIONS/GRANTS:
GRANTS AWARDED: TOTAL £3,596,774 (all grant holders are included in each grant provided below)
- UKRI EPSRC (£790,000) N Leslie (CI), O Oikonomidou, Maiwenn Kersaudy-Kerhoas: MicroSNARE: Automated Enrichment Of Circulating Tumour DNA For Improved Cancer Treatment. May 2024.
The grant will be shared by the 3 key grant holders as above. My contribution is crucial given that I will validate in my lab all the preliminary data. - UKRI EPSRC (£159,891) Anitha Devadoss (CI), Olga Oikonomidou: Electrochemical Profiling of Extracellular Vesicles (EP4EVs) to monitor therapeutic efficacy of neoadjuvant chemotherapy. March 2024. We are only 2 people in this grant and again validation and clinical correlation of this technique on the neoadjuvant setting to monitor treatment efficacy.
- NCRI M2C (£400,000) December 2022 Carlo Palmieri, Olga Oikonomidou. HER2-CNS SURVEILLANCE: A Study of the feasibility of randomising women and men with HER2 Positive metastatic breast cancer to Central Nervous System surveillance versus not.
This grant will be used to fund the additional imaging we propose in this group of patients with high risk of CNS involvement secondary to breast cancer. We strongly believe that these patients require surveillance and that our data will support the development of a new national consensus. - A multinational observational study characterizing utilization and effectiveness outcomes in patients with MBC receiving Abemaciclib (£90.000) Olga Oikonomidou. Project completed October 2023. Manuscript under preparation.
- Real-World Clinical Outcomes Associated with First-Line Palbociclib and Aromatase Inhibitor Therapy Among Patients with HR+/HER2− Advanced Breast Cancer in Europe. (£65.000) Olga Oikonomidou. The funds were used to fund a data collector/analyst post who worked under my supervision. Paper has been accepted for publication September 2024 at the ‘’Cancer Research & Treatment’’.
- BCI grant (£150,000) March 2021 Olga Oikonomidou: Comprehensive profiling of clonal dynamics in longitudinal TNBC samples from early disease to metastatic setting.
Funds were used to cover the NGS sequencing and other lab expenses. - BCI grant (£100,000) September 2019 Arran Turnbull (CI), Olga Oikonomidou: Genomics of Endocrine Therapy Resistance – Tailoring Treatment using Personalised Genomic Analysis. Funds were used to cover the NGS sequencing and other lab expenses.
- Make2ndsCount (£190,000) June 2019 Olga Oikonomidou: Identification of biomarkers of response to CDK4/6 inhibitors in cfDNA sequential samples from patients with secondary breast cancer. November 2019. Funds were used to support the translational element of the study and partly the salary of my postdoc fellow.
- CRUK Early Cancer Detection initiative (£475,000) Tim Aitman (CI), Charlie Gourley, Duncan Sproul, Margaret Frame, Olga Oikonomidou. ‘’ Multiplex methylation analysis of cell-free DNA for early cancer diagnosis February 2018.
- NIHR National Institute for Health Research £781,000 (EME) Peter Henriksen (CI), Peter Hall, Olga Oikonomidou, Scott Semple : “Cardiac CARE: A multicentre prospective randomised open-label blinded endpoint-controlled trial of cardiac troponin guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients”, September 2017. Funds were used to support the clinical trial recruitment, tests, analysis, and MRIs.
- Chief Scientist Office Research Grant (£220,883) Nicholas Leslie, Olga Oikonomidou : Novel sample preparation for improved circulating tumour DNA analysis. July 2015. Funds were split up between the two groups to cover the analysis and NGS costs.
- MRC Confidence in Concept Scheme (£60,000) Olga Oikonomidou: Bioinformatics analysis of the NEO pilot study. 2 years from May 2014. All funds were used for the transcriptomics analysis of the NEO samples.
- Margaret Lee fund (£90,000) Scott Semple, Martin Denver, Olga Oikonomidou: The role of Magnetic Resonance Phosphorous Spectroscopy (31P-MRS) in detecting changes in heart function associated with the use of chemotherapy drugs used to treat breast cancer. December 2014.
Funds were used to support the pilot study recruitment, tests, analysis and MRIs. - CRUK Grant-Development Fund (£25,000) Olga Oikonomidou: for ‘’The NEO study: a study of factors predicting response to neoadjuvant chemotherapy in breast cancer patients’’. April 2014. Funds were used for the DNA/RNA extractions and microarrays.
KNOWLEDGE EXCHANGE AND IMPACT:
INVITED SPEAKER TALKS ( only a small representative sample of international and national talks given over the last 5 years):
- Advances in breast cancer hub, April 2025, Birmingham UK.
- TNBC treatment landscape. 28 February 2025. London, UK.
- Emerging therapeutics in HR+ Early Breast Cancer. EBCSS 2025 conference. February 2025, Edinburgh, UK.
- Roundtable meeting in the Scottish Parliament on Scotland’s Cancer Action Plan and Breast Cancer. 28 January 2025. Scottish Parliament.
- Association of Breast Surgery: ‘’The axilla for the Medical Oncologist’’. The Royal College of Surgeons. London January 2025.
- HR+ HER2-ve treatment landscape. 11 November 2024. Adelaide, Australia.
- Scientific Exchange Meeting 12 November 2024. Melbourne, Australia.
- Navigating the HR+ HER2- Breast Cancer Continuum: Verzenio – Different by Design. 13 November 2024. Sydney, Australia.
- Early Breast Cancer HR+ HER2+ve” What is next? COSA Conference 2024, 14 November, Gold Coast, Australia.
- HER2 Horizons meeting: Destiny-Breast04 data & the clinical implementation of HER2-Low. London October 2024.
- 8th world Congress in Breast Cancer Controversies Edinburgh September 2024.
- Debate: ’’All stage 2/3 TNBC patients should be treated according to Keynote 522 regimen’’: YES!
- Ribociclib in an eligible HR+/HER2- aBC patient with cardiac comorbidities. Industry symposium.
- Unlocking insights for HER2-low mBC: A deep dive into DESTINY-Breast04. Industry symposium.
- Breast cancer systemic treatment in 2035
- National Oncology Masterclass in London (June 2024): I chaired the Genomics session and presented the update on NATALEE trial, chaired, and participated to the ASCO highlights session, I gave a lecture on ILD management.
- MSc course in Endocrinology June 2024 (Medical School of Athens) online presentation on ‘’Principles of systemic treatment in breast cancer’’.
- University of Hull Biannual Breast Cancer Meeting April 2024: ‘’Clinical implications of breast cancer intrinsic subtypes’’.
- University of Manchester, Prescribers teaching course March 2024: ‘’An A to Z of Metastatic Breast Cancer including Sequencing Treatment Options ’’February 2024.
- UAE Dubai SABCS highlights conference February 2024 (3 talks)
- ’PREVENT RECURRENCE, DELAY PROGRESSION’’.
- ‘’Importance of Diagnosing the right patient profile. Case by Case: Applying MonarchE Data into Practice’’.
- ’MonarchE 5-Year Data: Taking hope Further for HR+,HER2-, node-positive EBC patients.’’
- Webinar funded by pharma: ‘’mTNBC treatment pathway in 2024’’.
- Sheffield Teaching Hospital January 2024: “”Introducing Trodelvy® (sacituzumab govitecan): key facts about mTNBC and data from the phase 3 ASCENT trial’’.
- National IVF meeting December 2023 (Athens): ‘’Pregnancy related breast cancer-current data and the impact from Positive Trial’’.
- UAE Abu Dhabi Conference November 2023 (3 talks):
- HR+, HER2− MBC CDK4/6 inhibitors & beyond
- Sequencing of ADCs in TNBC cancer
- Long-term outcomes with adjuvant CDK 4/6 inhibitors- focus on Abemaciclib
- Kuwait National Cancer Centre November 2023: ‘’Tailored treatments in advanced HR+ HER2-ve breast cancer’’.
- Broadcast Webinar November 2023: ‘’HR+/HER2− aBC: How the latest survival data can help to inform your first-line choice of CDK4/6 inhibitor’’.
- New Horizons meeting London RCP October 2023 : ‘’Beyond CDK4/6 on the MBC setting’’ and ‘’ Case by Case: Applying MonarchE Data into Practice’’.
- Edinburgh Breast Cancer Symposium February 2023: ‘’Update on CDK4/6 inhibitors’’.
- Scottish Launch meeting of Adjuvant Abemaciclib – Edinburgh November 2022
- ESMO 2022 highlights presentation- Scottish meeting funded by ROCHE November 2022
- National Launch meeting of Adjuvant Abemaciclib – Keynote Speaker presenting the data from MONARCHE study, Royal College of Physicians - September 2022
- Novartis Masterclass June 2022 – London UK (presenting and chairing the Genomics session)
- UK Oncology Forum June 2022 – Belfast Ireland – ASCO & SABCS 2022 highlights
- National Launch meeting of Sacituzumab Govitecan – Ascent 3 data presentation May 2022
- National Oncology Forum – Novartis symposium: How to select CDK4/6i? October 2021
- Trastuzumab Deruxtecan Launch Meeting April 2021 funded by AZ/Daiichi Sankyo: Expanding the landscape of third-line treatments for patients with HER2+ metastatic breast cancer
- Alpelisib Launch Meeting March 2021 funded by Novartis: SOLAR-1 data
- Edinburgh Breast Cancer Symposium February 2021:
- ER+ve MBC optimal treatment sequencing
- Management of PD-L1 negative metastatic TNBC: Current & novel therapeutics
- Hong Kong Breast Cancer Symposium February 2021
- Principles of Endocrine treatment in breast cancer
- Principles of chemotherapy in Breast cancer
- Optimal treatment in HER2+ve in MBC
- San Antonio Highlights meeting January 2021 funded by Astra Zeneca and Daiichi Sankyo: ‘’SABCS scientific exchange meeting’’.
- Parliamentary talk November 2021 funded by Exact Sciences ‘’Genomics vs Genetics’’
- Webinar November 2021 funded by Pfizer ''Covid-19 impact’’
- UK National Oncology Forum October 2020 (virtual meeting): ‘’ESMO 2020 highlights’’
- ESMO Highlights meeting October 2020 funded by Novartis (virtual meeting) ‘’ESMO 2020 highlights’’
- Webinar May 2020 funded by Pfizer ‘’Palbociclib RWD: NHS Lothian experience’’
- Webinar May 2020 funded by Pfizer ‘’Paloma 2 & 3 data’’
- First Thoughts meeting February 2020 funded by EISAI: ‘’The tale of the 3 ciclibs’’
- Webinar January 2020 funded by Pfizer ‘’Palbociclib toxicities’’
EXTERNAL RECOGNITION / ESTEEM:
- National Institute for Clinical Excellence Technology Appraisal Committee Member (2017-current)
- Scottish Medicines Consortium Technology Appraisal Committee Member (2016-current)
- NIHR, CSO and MRC, Irish and Yorkshire Research Fund expert reviewer
- Scottish Clinical Trials Committee Member
- Make2ndsCount Charity Research Advisory Committee
- National Breast Imaging Academy e-learning programme: Breast Cancer Sessions Module Editor
- Member of the National Oncology committee. Disseminate data, information, and guidance from meeting on regular basis to update local practice.
- The more than 50 talks in International and National meetings over the last 3 years supports my role as a Key Opinion Leader in the field of breast cancer.
- I was invited to join Frontiers in Oncology as Editor (2022-current).
RECOGNITION – AWARDS:
- SCOTTISH WOMEN AWARDS 2018 and 2019 shortlisted among all women health care professionals (HCP) in Scotland (included both nurses and doctors) in the top 8 women (HCP) for the award ‘’SERVICES IN MEDICINE’’
- https://www.ed.ac.uk/institute-genetics-cancer/news-and-events/news-2019/our-academic-consultant-oncologist-among-the-final
- https://news.nhslothian.scot/Pages/20180911_RunningForTheScottishWomensAward.aspx
- https://twitter.com/edincrc/status/1166314634833530880?lang=bg
PUBLICATIONS:
PUBLICATIONS: 1. Charting the longitudinal mutational landscape of triple negative breast cancer. Devin P Bendixsen1, Fiona Semple, Alastair Ironside, Natalie Wilson, Alison Meynert, Ailith Ewing, Colin Semple, Olga Oikonomidou. Submitted for publication. 2. Real-World Clinical Outcomes Associated With First-Line Palbociclib and Aromatase Inhibitor Therapy Among Patients With HR+/HER2− Advanced Breast Cancer in Europe. Olga Oikonomidou, Achim Woeckel, Elena Galve-Calvo, Mark Beresford, Rohan C Parikh, Justin Doan, Connie Chen, Benjamin Li, Valerie Ansquer Derrien, Gaelle Frugier, Abigail Hitchens, Maria Jimenez, Keith Davis, Edward I Broughton. Accepted for publication at ‘’Breast Cancer Research and Treatment’’. (March 2025) 3. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Peter A Henriksen, Peter Hall, Iain R MacPherson, Shruti S Joshi, Trisha Singh, Morag Maclean, Steff Lewis, Aryelly Rodriguez, Alex Fletcher, Russell J Everett, Harriet Stavert, Angus Broom, Lois Eddie, Lorraine Primrose, Heather McVicars, Pam McKay, Annabel Borley, Clare Rowntree, Simon Lord, Graham Collins, John Radford, Amy Guppy, Michelle C Williams, Alan Japp, John R Payne, David E Newby, Nicholas L Mills, Olga Oikonomidou, Ninian N Lang. Circulation 148 (21), 1680-1690 * (2022) |
4. Single-cell RNA sequencing of human breast tumour-infiltrating immune cells reveals a γδ T-cell subtype associated with good clinical outcome. Katerina Boufea, Victor Gonzalez-Huici, Marcus Lindberg, Nelly N Olova, Stefan Symeonides, Olga Oikonomidou, Nizar N Batada. Life Science Alliance 6 (2), e202201848-e202201848 (2022) |
5. Rationale and design of the Cardiac CARE Trial: a randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. PA Peter A Henriksen, Peter Hall, Olga Oikonomidou, Iain R MacPherson, Morag Maclean, Steff Lewis, Heather McVicars, Angus Broom, Fiona Scott, Pam McKay, Annabel Borley, Clare Rowntree, Simon Lord, Graham Collins, John Radford, Amy Guppy, John R Payne, David E Newby, Nick L Mills, Ninian N Lang. Circulation: Heart Failure 15 (7)* (2022) |
6. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Ernest H Law, Elena Galve-Calvo, Achim Wockel, Rohan Parikh, Samantha K Kurosky, Valerie Derrien Ansquer, Gaelle Frugier, Keith L Davis, Elizabeth J Esterberg, Olga Oikonomidou. CANCER RESEARCH 82 (4) * (2022) |
7. Primary acinic cell carcinoma of the breast is associated with a poor outcome: a case report and literature review. L Sarsiat, G Watkinson, A Turnbull, A Diana, O Oikonomidou. Molecular and Clinical Oncology 16 (2), 1-8 (2022) |
8. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Virginia Alvarez-Garcia, Clare Bartos, Ieva Keraite, Urmi Trivedi, Paul M Brennan, Maiwenn Kersaudy-Kerhoas, Karim Gharbi, Olga Oikonomidou, Nicholas R Leslie. SCIENTIFIC REPORTS 11 (1) (2021) |
9. Expert Discussion: HER2-Positive Breast Cancer. Theo Foukakis, Alexios Matikas, Olga Oikonomidou, E Andreopoulou, D Mavroudis. Breast Care 16 (4), 422-428 * (2021) |
10. Cardiac Energetics Before, During, and After Anthracycline-Based Chemotherapy in Breast Cancer Patients Using 31P Magnetic Resonance Spectroscopy: A Pilot Study. Gillian Macnaught, Olga Oikonomidou, Christopher T Rodgers, William Clarke, Annette Cooper, Heather McVicars, Larry Hayward, Saeed Mirsadraee, Scott Semple, Martin A Denvir. Frontiers in Cardiovascular Medicine 8, 653648 (2021) |
11. Risk of chemotherapy-related amenorrhoea (CRA) in premenopausal women undergoing chemotherapy for early stage breast cancer. AK Turnbull, S Patel, C Martinez-Perez, A Rigg, O Oikonomidou. Breast cancer research and treatment 186, 237-245 (2021) |
12. Lobular breast cancer: a review. N Wilson, A Ironside, A Diana, O Oikonomidou. Frontiers in oncology 10, 591399 * (2021) |
13. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Virginia Alvarez-Garcia, Clare Bartos, Ieva Keraite, Urmi Trivedi, Paul M Brennan, Maïwenn Kersaudy-Kerhoas, Karim Gharbi, Olga Oikonomidou, Nicholas R Leslie. Scientific Reports 11 (2021) |
14. PIK3CA mutation enrichment and quantitation from blood and tissue. Ieva Keraite, Virginia Alvarez-Garcia, Isaac Garcia-Murillas, Matthew Beaney, Nicholas C Turner, Clare Bartos, Olga Oikonomidou, Maïwenn Kersaudy-Kerhoas, Nicholas R Leslie. Scientific reports 10 (1), 17082 (2020) |
15. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Nicholas C Turner, Belinda Kingston, Lucy S Kilburn, Sarah Kernaghan, Andrew M Wardley, Iain R Macpherson, Richard D Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Hannah Bye, Michael Hubank, Heidrun Gevensleben, Ros Cutts, Claire Snowdon, Daniel Rea, David Cameron, Abeer Shaaban, Katrina Randle, Sue Martin, Katie Wilkinson, Laura Moretti, Judith M Bliss, Alistair Ring. The Lancet Oncology 21 (10), 1296-1308 * (2020) |
16. Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy. E Tzolos, PD Adamson, Peter S Hall, IR Macpherson, O Oikonomidou, M MacLean, SC Lewis, H McVicars, DE Newby, NL Mills, NN Lang, PA Henriksen. Clinical Oncology 32 (5), 292-297 (2020) |
17. Patient and clinician engagement statements as a tool to explore patient preferences for metastatic breast cancer treatments in Scotland. Alistair Bullen, Holly Ennis, Lauren Murdoch, Ewan Gray, Emily Ross, Olga Oikonomidou, Morag McIntyre, Nicolas Krucien, Mandy Ryan, Peter Hall. BREAST CANCER RESEARCH AND TREATMENT 180 (2), 579-579. (2020) |
18. Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes. Anna Diana, Francesca Carlino, Elisena Franzese, Olga Oikonomidou, Carmen Criscitiello, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura. Cancers 12 (4), 819 * (2020) |
19. Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data. Olga Oikonomidou, Evangelos Tzolos, Philip D Adamson, Peter S Hall, Iain R MacPherson, Morag MacLean, Steff Lewis, Heather McVicars, David E Newby, Nicholas L Mills, Ninian Lang, Peter A Henriksen. CANCER RESEARCH 80 (4) (2020) |
20. Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets. Olga Oikonomidou, Ashley Horne, M McMenemy, E Holly, L Murdoch, Caroline Michie, Richard L Hayward, Christina Lilley, Peter S Hall. CANCER RESEARCH 80 (4) (2020) |
21. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. Richard J Bownes, Arran K Turnbull, Carlos Martinez-Perez, David A Cameron, Andrew H Sims, Olga Oikonomidou. Breast Cancer Research 21, 1-12 * (2019) |
22. Real-world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets. AWB Horne, Maria McMenemy, E Holly, N Rigglesford, P Linksted, L Murdoch, O Oikonomidou, C Michie, L Hayward, Christina Lilley, Peter Hall. Annals of Oncology 30, v137 (2019) |
23. Dynamic changes in high sensitivity cardiac troponin I in response to anthracycline-based chemotherapy: a pilot study for the cardiac care trial. Philip D Adamson, Peter Hall, Ninian Lang, Iain Macpherson, Olga Oikonomidou, Morag Maclean, Steff Lewis, Heather McVicars, David Newby, Nicholas Mills, Peter Henriksen. Journal of the American College of Cardiology 71 (11S). (2018) |
24. A simple and robust real-time qPCR method for the detection of PIK3CA mutations. Virginia Alvarez-Garcia, Clare Bartos, Ieva Keraite, Urmi Trivedi, Paul M Brennan, Maïwenn Kersaudy-Kerhoas, Karim Gharbi, Olga Oikonomidou, Nicholas R Leslie. Scientific Reports 8 (1), 4290 (2018) |
25. Surgery: Core Principles & International Practice. 2nd Edition 2017. JP Brothers Medical Publishers. “Practical Problems: Hypercalcaemia in breast disease”. O Oikonomidou. JP Medical Ltd (2016) |
26. A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib. O Oikonomidou, S Aylwin, P Ross, D Sarker. Neuroendocrinology 96 (2012) |
27. Glucocorticoid receptor, nuclear factor κB, activator protein-1 and C-jun N-terminal kinase in systemic lupus erythematosus patients. O Oikonomidou, PG Vlachoyiannopoulos, A Kominakis, A Kalofoutis. Neuroimmunomodulation 13 (4), 194-204. (2007) |
POSTER PRESENTATIONS:
POSTER PRESENTATIONS: 1. Charting the longitudinal mutational landscape of triple negative breast cancer. Devin P Bendixsen1, Fiona Semple, Alastair Ironside, Natalie Wilson, Alison Meynert, Ailith Ewing, Colin Semple, Olga Oikonomidou. SABCS 2024 P2-03-23. (2024) 2. Shallow whole genome sequencing of cell free DNA to predict response to CDK4/6 inhibitor treatment in ER+/HER2- metastatic breast cancer. Fiona Semple, John P. Thomson, Natalie Wilson and Olga Oikonomidou. SABCS 2024 P2-03-22. (2024) 3. Real world experience of Trastuzumab Deruxtecan for the treatment of metastatic breast cancer in the UK. Andy Cheng, Suzanne Frank, Katherine Baines, Mark Nathan, Rosalie V Douglas, Rushan Sylva, Jessica Ball, Constantinos Savva, Thomas Talbot, Olga Oikonomidou, Jenny Smith, Alastair Thomson, Felicity Ross, Apostolos Konstantis, Nicola Ainsworth, Pietro Luciano, Pooja Iyer, Shyamika Acharige, Shaikh Rana, Judy King. Journal of Clinical Oncology 42 (16_suppl), 1024-1024 * (2024) 4. Charting the mutational landscape of triple negative breast cancer tumours during treatment. Devin P Bendixsen, Fiona Semple, Alastair Ironside, Natalie Wilson, Alison Meynert, Ailith Ewing, Colin Semple, Olga Oikonomidou. 15-17 Nov 2023, EMBL Cancer Genomics, Heidelberg, Germany (2024) |
5. Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Alicia Frances Clare Okines, Jeremy Braybrooke, Iain R MacPherson, Dr Stephanie Sutherland, Sacha Jon Howell, Duncan Wheatley, Simon Waters, Rebecca Roylance, Richard D Baird, Olga Oikonomidou, Carlo Palmieri, Mark Harries, Catherine Harper-Wynne, Amna Sheri, Sarah Khan, Catey Bunce, Kabir Mohammed, Dymphna Lee, Nicholas C Turner. Journal of Clinical Oncology 41 (16_suppl), TPS1111 (2023) |
6. 213P Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2-advanced breast cancer in Europe. O Oikonomidou, E Galve-Calvo, A Wöckel, R Parikh, A Hitchens, C Chen, E Gauthier, B Li, V Derrien Ansquer, G Frugier, M Jimenez, K Davis, E Broughton. ESMO Open Volume 8 Issue 1 (2023) |
7. Abstract OT2-19-04: European treatment patterns and outcomes associated with first line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Ernest H Law, Elena Galve-Calvo, Achim Wöckel, Rohan Parikh, Samantha K Kurosky, Valerie Derrien Ansquer, Gaelle Frugier, Keith L Davis, Elizabeth J Esterberg, Olga Oikonomidou. Cancer Research 82 (4_Supplement), OT2-19-04-OT2-19-04 (2022) |
8. Abstract P1-02-04: Modified Miller-Payne score as a pragmatic and efficient alternative to Residual Cancer Burden Peter S Hall, Alistair Ironside, Giovanni Tramonti, Alex Cavanagh, Katy Quiohilag, Olga Oikonomidou. Cancer Research 82 (4_Supplement), P1-02-04-P1-02-04 (2022) |
9. Abstract P1-08-30: Validation of the AAGAB gene as a novel on-treatment biomarker predicting pCR in patients receiving NACT for early breast cancer. Fiona Semple, Alastair Ironside, Richard Bownes, Carlos Martinez-Perez, Natalie Wilson, Arran Turnbull, Olga Oikonomidou. Cancer Research 82 (4_Supplement), P1-08-30-P1-08-30 (2022) |
10. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Ernest H Law, Elena Galve-Calvo, Achim Wockel, Rohan Parikh, Samantha K Kurosky, Valerie Derrien Ansquer, Gaelle Frugier, Keith L Davis, Elizabeth J Esterberg, Olga Oikonomidou. CANCER RESEARCH 82 (4) * (2022) |
11. Palbociclib real-world data in metastatic breast cancer: A multi-site report of survival and adverse events in routine clinical practice in Scotland. AJ Oswald, P Hall, A Turnbull, O Oikonomidou. Cancer Research 81 (4_Supplement), PS10-55-PS10-55 (2021) |
12. 173P Prognostic impact of progesterone receptor levels in luminal-like Her2-early breast cancer patients: A retrospective analysis. F Carlino, A Diana, G Buono, G Arpino, E Franzese, O Oikonomidou, V Famiglietti, G Signoriello, F De Vita, F Ciardiello, M Orditura. Annals of Oncology 31, S31 (2020) |
13. Abstract P1-13-02: Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data. Olga Oikonomidou, Evangelos Tzolos, Philip D Adamson, Peter S Hall, Iain R MacPherson, Morag MacLean, Steff Lewis, Heather McVicars, David E Newby, Nicholas L Mills, Ninian Lang, Peter A Henriksen. Cancer Research 80 (4_Supplement), P1-13-02-P1-13-02 (2020) |
14. Abstract P1-01-03: Association of cardiac energetics and plasma biomarkers with anthracycline-based chemotherapy in breast cancer patients. Olga Oikonomidou, Gillian Macnaught Macnaught, Christopher T Rodgers, William Clarke, Annette Cooper, Heather McVicars, Arran K Turnbull, Saeed Mirsadraee, Scott Semple, Martin Denvir. Cancer Research 80 (4_Supplement), P1-01-03-P1-01-03 (2020) |
15. Abstract P1-18-07: Can some ER+/HER2+ patients be safely spared from treatment with chemotherapy plus herceptin? Arran K Turnbull, Victoria Webber, Daniel McStay, Laura M Arthur, Carlos Martinez-Perez, James Meehan, Mark Gray, Charlene Kay, Lorna Renshaw, Jane Keys, Robert Clarke, Andrew H Sims, Olga Oikonomidou, J Michael Dixon. Cancer Research 80 (4_Supplement), P1-18-07-P1-18-07 (2020) |
16. Abstract P6-10-18: Development and validation of novel biomarkers of response to radiotherapy in breast cancer. James Meehan, Mark Gray, Carlos Martinez-Perez, Charlene Kay, J Michael Dixon, Jimi Wills, Carol Ward, Alex von Kriegsheim, Niall Quinn, Olga Oikonomidou, David Cameron, Simon P Langdon, David Argyle, Ian H Kunkler, Arran K Turnbull. Cancer Research 80 (4_Supplement), P6-10-18-P6-10-18 (2020) |
17. Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer. Nicholas Turner, Belinda Kingston, Lucy Kilburn, Sarah Kernaghan, Andrew M Wardley, Iain Macpherson, Richard D Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Hannah Bye, Michael Hubank, Claire Snowdon, Daniel Rea, David Cameron, Abeer Shaaban, Katrina Randle, Katie Wilkinson, Laura Moretti, Judith M Bliss, Alistair Ring. Cancer Research 80 (4_Supplement), GS3-06-GS3-06 (2020) |
18. Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing. Richard D Baird, Lucy Kilburn, Sarah Kernaghan, Andrew M Wardley, Iain Macpherson, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Belinda Kingston, Katie Wilkinson, Nicholas Turner, Alistair Ring, Judith M Bliss. Cancer Research 80 (4_Supplement), P1-19-14-P1-19-14 (2020) 19. Results of Plasma MATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening. Baird RD, Kilburn L, Kernaghan S, Wardley AM, Macpherson I, Roylance R, Stephens P, Oikonomidou O, Braybrooke JP, Tuthill M, Abraham J, Winter MC, Kingston B, Wilkinson K, Turner N, Ring A, Bliss JM. (2020) |
20. Abstract P2-17-04: Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets. Olga Oikonomidou, Ashley Horne, M McMenemy, E Holly, L Murdoch, Caroline Michie, Richard L Hayward, Christina Lilley, Peter S Hall. Cancer Research 80 (4_Supplement), P2-17-04-P2-17-04 (2020) |
21. Abstract P6-16-04: IL6ST, a biomarker of endocrine therapy response, has potential in identifying a subgroup of women with ER+ DCIS who are more likely to benefit from adjuvant endocrine therapy. Carlos Martinez-Perez, Charlene Kay, Rebecca Swan, Gregory E Ekatah, Laura M Arthur, James Meehan, Mark Gray, Andrew H Sims, Olga Oikonomidou, Arran K Turnbull, J Michael Dixon. Cancer Research 80 (4_Supplement), P6-16-04-P6-16-04 (2020) |
22. Abstract P6-04-03: In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer. Arran K Turnbull, Youli Xa, Carlos Martinez-Perez, Olga Oikonomidou, James Meehan, Mark Gray, Lisa A Carey, Charles M Perou, J Michael Dixon. Cancer Research 80 (4_Supplement), P6-04-03-P6-04-03 (2020) |
23. Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with a HER2 mutation identified via ctDNA screening. Andrew M Wardley, Lucy Kilburn, Sarah Kernaghan, Iain Macpherson, Richard D Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Belinda Kingston, Katie Wilkinson, Judith M Bliss, Alistair Ring, Nicholas Turner. Cancer Research 80 (4_Supplement), P1-19-07-P1-19-07. (2020) |
24. Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening. Iain Macpherson, Lucy Kilburn, Sarah Kernaghan, Andrew M Wardley, Richard D Baird, Rebecca Roylance, Peter Stephens, Olga Oikonomidou, Jeremy P Braybrooke, Mark Tuthill, Jacinta Abraham, Matthew C Winter, Belinda Kingston, Katie Wilkinson, Alistair Ring, Judith M Bliss, Nicholas Turner. Cancer Research 80 (4_Supplement), P1-19-04-P1-19-04 (2020) |
25. Abstract P2-11-06: Assessment of ESR1 genomic aberrations and their role in endocrine therapy resistance in breast cancer. Carlos Martinez-Perez, Charlene Kay, James Meehan, Mark Gray, Rebecca Swan, Lorna Renshaw, Jane Keys, Andrew H Sims, Olga Oikonomidou, J Michael Dixon, Arran K Turnbull. Cancer Research 80 (4_Supplement), P2-11-06-P2-11-06 (2020) |
26. Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data. Olga Oikonomidou, Evangelos Tzolos, Philip D Adamson, Peter S Hall, Iain R MacPherson, Morag MacLean, Steff Lewis, Heather McVicars, David E Newby, Nicholas L Mills, Ninian Lang, Peter A Henriksen. CANCER RESEARCH 80 (4) (2020) |
27. Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets. Olga Oikonomidou, Ashley Horne, M McMenemy, E Holly, L Murdoch, Caroline Michie, Richard L Hayward, Christina Lilley, Peter S Hall. CANCER RESEARCH 80 (4) (2020) |
28. Real-world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets. AWB Horne, Maria McMenemy, E Holly, N Rigglesford, P Linksted, L Murdoch, O Oikonomidou, C Michie, L Hayward, Christina Lilley, Peter Hall. Annals of Oncology 30, v137 (2019) |
29. Abstract P3-11-13: On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer. RJ Bownes, AK Turnbull, D Cameron, AH Sims, O Oikonomidou. Cancer Research 79 (4_Supplement), P3-11-13-P3-11-13 (2019) |
30. Dynamic changes in high sensitivity cardiac troponin I in response to anthracycline-based chemotherapy: a pilot study for the cardiac care trial. Philip D Adamson, Peter Hall, Ninian Lang, Iain Macpherson, Olga Oikonomidou, Morag Maclean, Steff Lewis, Heather McVicars, David Newby, Nicholas Mills, Peter Henriksen. Journal of the American College of Cardiology 71 (11S), A701-A701 (2018) |
31. Abstract P4-14-12: Influence of socio-economic deprivation score on outcomes for patients diagnosed with early breast cancer over a 9 year follow up at Kings College Hospital, UK. O Oikonomidou, M Ofuya, AS Rigg. Cancer Research 75 (9_Supplement), P4-14-12-P4-14-12 (2015) |
32. A Case Report of a Patient with Metastatic Cervical Paraganglioma Responding to the Tyrosine Kinase Inhibitor Sunitinib. O Oikonomidou, S Aylwin, P Ross, D Sarker. Neuroendocrinology 96 (2012) |
33. Venous Thrombosis Rates in Early Breast Cancer Patients Receiving Standard Chemotherapy, a Retrospective Analysis. Investigation and Treatment of Upper Limb Symptoms. J Kahan, O Oikonomidou, N Greenwood, T Marler-Hausen, A Rigg. European Journal of Cancer, S238 (2011) |
Get in Touch
For inquiries, bookings, or more information, please reach out
